Introduction
============

Hypertension is a major public health problem that is associated with significant cardiovascular morbidity and mortality. There is a growing body of evidence which shows that antihypertensive therapy substantially reduces the incidence of cardiovascular disease, provided that the blood pressure (BP) is controlled tightly.^[@bib1],[@bib2]^ To achieve sufficiently tight BP control, it is often necessary to employ combination therapy with multiple antihypertensive agents of different classes,^[@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7],\ [@bib8]^ but the optimum combination has not yet been elucidated. In recent clinical practice, an angiotensin receptor blocker (ARB) combined with a calcium channel blocker (CCB) or an ARB combined with a diuretic have been widely used for the treatment of hypertension.^[@bib6]^ However, it is still unclear which combination is more beneficial for the prevention of cardiovascular disease, as well as which is better with regard to safety and tolerability. Combination of olmesartan and a CCB or a diuretic in Japanese elderly hypertensive patients (COLM) trial was a prospective, randomized, open-label, blinded-endpoint (PROBE) study to determine which combination is a preferable therapy for hypertension, ARB plus CCB or ARB plus diuretic,^[@bib9],[@bib10]^ and the principal results have demonstrated that there were no remarkable differences in the primary composite endpoints of cardiovascular morbidity and mortality between the two groups, olmesartan plus CCB or diuretic.^[@bib8]^ However, safety and tolerability profiles suggested that olmesartan plus CCB may be preferable to olmesartan plus diuretic.^[@bib8]^ In this article, the details of the COLM-study findings with respect to safety and tolerability are reported.

Methods
=======

The rationale, design, management and principal results of the COLM study have already been reported.^[@bib9],[@bib10]^

In brief, hypertensive patients aged 65--84 years, with a history of cardiovascular disease and/or cardiovascular risk factors, who had a systolic BP ⩾140 mm Hg and/or diastolic BP ⩾90 mm Hg while on antihypertensive treatment or a systolic BP ⩾160 mm Hg and/or diastolic BP ⩾100 mm Hg without treatment, were randomized to receive olmesartan plus either a CCB (amlodipine or azelnidipine) or a low-dose diuretic (trichlormethiazide, indapamide or some other thiazide) for at least 3 years. The target BP was \<140/90 mm Hg.

The primary endpoint was the occurrence of fatal or non-fatal cardiovascular events, including sudden death, fatal and non-fatal stroke including transient ischemic attack, fatal and non-fatal cardiac events and renal events.

Secondary endpoints were as follows: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke (all of which cause death) a composite hard endpoint (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, excluding transient ischemic attack), new-onset of diabetes, the incidence of specific events (sudden death, cerebrovascular events, cardiac events and renal events), new-onset of atrial fibrillation, adverse events (AEs) and the discontinuation rate for each allocated treatment. AEs were classified as drug related or nondrug related and as serious or non serious, and were monitored throughout the study.

All cardiovascular events and serious AEs (SAEs) reported by the participating investigators were adjudicated by the Endpoint committee that was blinded to the study group.

Statistical analysis
--------------------

Patient characteristics were reported as mean±s.d. or percentage. The frequency rates of AEs were compared by using Fischer\'s exact test. Student\'s *t*-test was used to compare the two groups. Time-to-continuation curves were drawn with the Kaplan--Meier method for the continuation rates in each treatment group and the stratified log-rank test was used to compare these rates between the two groups. Repeated measures analysis of variance was used to compare the changes of estimated glomerular filtration rate between the two groups. All statistical analyses were done with SAS 9.1 software (SAS Institute, Cary, NC, USA).

Results
=======

Study groups and baseline characteristics
-----------------------------------------

Details of the study groups and baseline characteristics were described in the previous report.^[@bib9]^ In brief, a total of 5658 patients were assessed for eligibility. After the 449 patients who met the exclusion criteria and the 28 patients who did not give consent were excluded, the remaining 5141 patients were randomly assigned for treatment with olmesartan plus a CCB (olmesartan plus CCB group) or olmesartan plus a diuretic (olmesartan plus diuretic group). A total of 46 patients in the olmesartan plus CCB group and 72 patients in the olmesartan plus diuretic group were lost to follow-up and 5023 patients (98%) completed the follow-up period. The mean follow-up period was 3.3 years, the mean age of the patients was 73.6 years and 51.6% of the subjects were men. There were no significant differences of baseline characteristics between the two treatment groups. About 24% of the patients had a history of cardiovascular disease, including stroke (14.6%) and ischemic heart disease (11.0%).

Safety and AEs
--------------

The olmesartan plus CCB group showed a lower incidence of all AEs, SAEs, drug-related SAEs and discontinuation due to SAEs than the olmesartan plus diuretic group ([Figure 1](#fig1){ref-type="fig"}). Conversely, the continuation rate was significantly lower in the olmesartan plus diuretic group than in the olmesartan plus CCB group (*P*\<0.001; [Figure 2](#fig2){ref-type="fig"}). In addition, the total discontinuation rate was lower in the olmesartan plus CCB group than in the olmesartan plus diuretic group (20.7% *vs.* 32.4%, *P*\<0.001).

[Table 1](#tbl1){ref-type="table"} summarizes SAEs reported in more than 10 patients from each group. The incidence of fracture (the fourth most frequent SAE) was significantly higher in the olmesartan plus CCB group than in the olmesartan plus diuretic group.

Regarding laboratory data, changes in serum levels of uric acid and creatinine were significantly greater in the olmesartan plus diuretic group than in the olmesartan plus CCB group (for both groups *P*\<0.001). There were significantly more patients with hyperuricemia in the olmesartan plus diuretic group than in the olmesartan plus CCB group (153/2573, 6.5% *vs.* 61/2568, 2.6% *P*\<0.001). None of the patients had an acute attack of gout.

Although the serum potassium level did not change significantly in either group, the serum sodium level was significantly lower in the olmesartan plus diuretic group than in the olmesartan plus CCB group ([Table 2](#tbl2){ref-type="table"}).

[Figure 3](#fig3){ref-type="fig"} shows the changes of estimated glomerular filtration rate throughout the study period and at the end of follow-up in the two groups. The time course of estimated glomerular filtration rate was significantly reduced in the olmesartan plus diuretic group compared with the olmesartan plus CCB group (*P*\<0.001).

Discussion
==========

Total discontinuation rate, incidences of AEs, SAEs, drug-related SAEs and discontinuation due to SAEs were lower in the olmesartan plus CCB group than in the olmesartan plus diuretic group.

In the ACCOMPLISH study, the total study drug discontinuation rate was similar for both the treatment groups, being 28.8% for the benazepril plus amlodipine group and 31.2% for the benazepril plus hydrochlorothiazide group. In contrast, the total study drug discontinuation rate was significantly lower for the olmesartan plus CCB group than the olmesartan plus diuretic group in the present study (*P*\<0.001).

In a double-blind comparison of CCB alone with diuretic, in Japanese elderly hypertensive patients, 6 out of 204 in patients with CCB and 9 out of 210 patients with diuretic discontinued treatment because of SAEs.^[@bib11]^

Laboratory abnormalities, such as elevation of uric acid, elevation of creatinine and a decrease of sodium, were more common in the olmesartan plus diuretic group than in the olmesartan plus CCB group and might have contributed to the higher incidence of SAEs in the olmesartan plus diuretic group. Concerning the lower incidence of fracture in the olmesartan plus diuretic group, treatment with a thiazide diuretic may have had a role because these diuretics decrease urinary excretion of calcium and influence bone metabolism,^[@bib12]^ although this could have been a chance finding.

Even with low-dose diuretic therapy, elevation of serum uric acid could not be avoided. In our previous study of combined treatment with hydrochlorothiazide (12.5 mg) and the ARB (losartan) for 8 weeks, the uric acid level increased significantly despite the uricosuric action of losartan.^[@bib13],\ [@bib14],\ [@bib15]^ Therefore, an increase of uric acid cannot be avoided by combining a thiazide diuretic with any type of ARB. Several studies have shown that the serum uric acid level is a predictor of cardiovascular events.^[@bib16],\ [@bib17],\ [@bib18],\ [@bib19]^

The significant reduction of estimated glomerular filtration rate caused by the combination of olmesartan and a diuretic during the early treatment period was probably related to the volume reduction induced by the diuretic.

Although there is a well-known relationship between the thiazide dose and changes in serum potassium, glucose and uric acid levels,^[@bib20]^ there was no significant difference in hypokalemia between the olmesartan plus CCB group and the olmesartan plus diuretic in the present study. Therefore, it seems that the combination of olmesartan plus a low-dose thiazide diuretic may not increase the risk of new-onset of diabetes. In fact, the combination of a thiazide diuretic and an angiotensin converting enzyme (ACE) inhibitor or an ARB is widely used clinically and appears to be associated with less risk of diabetes than combined therapy with a beta-blocker^[@bib5]^ or other antihypertensive drugs.

There were several limitations of the present study. First, this study used the PROBE method which has the potential drawback of investigator bias. Even though the endpoints, including the safety endpoints were reviewed by a blinded Endpoint committee, biased reporting of endpoints (particularly AEs) could possibly have occurred. However, BP control was similar in the two groups and it is unlikely that the PROBE design affected the main study outcomes. In addition, the sample size may not have been large enough. However, the actual incidence of primary endpoints was close to the expected rate of events, as shown in the design paper.

In conclusion, ARB plus CCB therapy was superior to the ARB plus diuretic therapy with regard to occurrence of AEs and study drug discontinuation.
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###### Serious adverse events and drug-related serious adverse events

                                                     *Serious adverse events*   *Drug-related serious adverse events*                                 
  -------------------------------------------------- -------------------------- --------------------------------------- ------- ---------- ---------- -------
  Malignancy                                         63 (2.5)                   80 (3.1)                                0.17                           
  Gastrointestinal disorder                          29 (1.1)                   27 (1.1)                                0.79    1 (0.04)   1 (0.04)   1.0
  Infection                                          24 (0.9)                   22 (0.9)                                0.76                           
  Fracture                                           22 (0.9)                   10 (0.4)                                0.034                          
  Arrhythmia                                         16 (0.6)                   18 (0.7)                                0.86    2 (0.1)    2 (0.1)    1.0
  Death of unknown cause (except for sudden death)   9 (0.4)                    12 (0.5)                                0.66                           
  Adverse effects on glucose metabolism              10 (0.4)                   10 (0.4)                                1.0                            
  Bone and joint impairment                          11 (0.4)                   8 (0.3)                                 0.50                           
  Syncope and dizziness                              8 (0.3)                    11 (0.4)                                0.64                           
  Renal dysfunction                                  11 (0.4)                   7 (0.3)                                 0.35    2 (0.1)    6 (0.2)    0.28
  Respiratory disorder                               10 (0.4)                   5 (0.2)                                 0.20                           
  Miscellaneous                                      46 (1.8)                   76 (3.0)                                0.008   5 (0.2)    16 (0.6)   0.026
  Total                                              211 (8.2)                  253 (9.8)                               0.046   9 (0.4)    22 (0.9)   0.029

Data are shown as number of patients (%), several patients had two or three adverse events. CCB, calcium channel blocker.

###### Biochemical variables at the baseline and at the end of study

                                  *Olmesartan plus CCB*   *Olmesartan plus diuretic*                                                       
  ------------------------------ ----------------------- ---------------------------- ------------ ------------ ------------- ------------ -----------
                                       *Baseline*                *36 months*            *Change*    *Baseline*   *36 months*    *Change*    P*-value*
  Hemoglobin (gdl^−1^)                  13.3±1.5                   13.0±1.4             −0.3±1.1     13.4±1.4     13.0±1.5      −0.3±1.2      0.080
  Sodium (mEql^−1^)                      141±2.3                   140±3.2              −0.3±3.2     141±2.6       140±3.6      −0.6±3.8      0.038
  Potassium (mEql^−1^)                   4.2±0.4                   4.2±0.4             0.02±0.47     4.1±0.4       4.2±0.4     0.04±0.51      0.31
  Uric acid (mgdl^−1^)                   5.5±1.3                   5.6±1.4              0.04±1.2     5.5±1.3       5.8±1.3      0.2±1.3      \<0.001
  Glucose (mgdl^−1^)                    119±41.1                   115±37.0            −4.3±40.3     119±44.0     114±36.0     −5.4±44.2      0.47
  Total cholesterol (mgdl^−1^)          203±37.3                   191±32.7            −12.0±38.8    204±38.2     190±32.0     −14.4±40.9     0.13
  HDL cholesterol (mgdl^−1^)            55.5±16.2                 56.4±15.5             0.9±12.6    55.6±15.9     55.9±15.8     0.3±13.0      0.17
  Triglyceride (mgdl^−1^)               142±76.2                   134±71.8            −8.2±74.3     139±78.1     134±74.0     −5.1±81.2      0.28
  Creatinine (mgdl^−1^)                 0.79±0.24                 0.84±0.36            0.05±0.25    0.80±0.22     0.89±0.42    0.09±0.33     \<0.001

Data are mean ±s.d., P-value for change in mean value between the two groups.
